[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499882":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":55,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group I","EXPERIMENTAL","Patients are treated with prednisone (≤20 mg qd, or equivalent glucocorticoid, taper to ≦ 5mg in 3 months) and iguratimod (25 mg bid).",[13],"Drug: glucocorticoid plus iguratimod",{"label":15,"type":10,"description":16,"interventionNames":17},"Group II","Patients are treated with prednisone (≤20 mg qd, or equivalent glucocorticoid, taper to ≦ 5mg in 3 months ) and leflunomide (10-20 mg qd).",[18],"Drug: glucocorticoid plus leflunomide",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","glucocorticoid plus iguratimod","Patients in Group I are treated with prednisone (≤20 mg qd, or equivalent glucocorticoid, taper to ≦ 5mg in 3 months) and iguratimod (25 mg bid).",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"glucocorticoid plus leflunomide","Patients in Group II are treated with prednisone (≤20 mg qd, or equivalent glucocorticoid, taper to ≦ 5mg in 3 months ) and leflunomide (10-20 mg qd).",[15],[31],{"name":32,"affiliation":5,"role":33},"Wen Zhang, MD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Yunyun Fei, MD","CONTACT","01069159953","feiyunyun@pumch.cn",[41],{"facility":5,"status":42,"city":43,"state":25,"zip":25,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Beijing","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53,54],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":33,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Wen Zhang","Professor","100499882","treatment-strategies-for-igg4-rd-patients-with-superficial-organ-involvement-100499882",false,"NCT05789030","Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement","Inclusion Criteria:\n\n* 1\\. Fulfillment of the 2019 American College of Rheumatology\u002FEuropean League against Rheumatology (ACR\u002FEULAR) IgG4-related disease classification criteria; 2. Newly-onset or relapsed patients who requires initiation or continuation of glucocorticoids treatment; 3. The addition of glucocorticoids was started at lower than 10 mg\u002Fd.\n\nExclusion Criteria:\n\n* 1\\. Patients who were diagnosed as other autoimmune diseases; 2. Patients who were diagnosed as malignant diseases; 3. Pregnant and lactating women； 4. Active infection: HIV, HCV, HBV, TB； 5. Severe irreversible damage of organ function; 6. Receipt of any biologic therapy or immunosuppressive agent other than GCs.","ALL","18 Years","75 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"NA","This study has been designed as a 12-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in IgG4-RD patients with superficial organ involvement: prednisone plus iguratimod and prednisone plus leflunomide.",[75],"Autoimmune Diseases",[77,78,79,80,81],"Immunoglobulin G4-Related Disease","treatment strategies","iguratimod","leflunomide","relapse","2026-04-01",{"date":84,"type":85},"2026-04-07","ACTUAL",{"date":87,"type":85},"2022-07-01",{"date":89,"type":69},"2026-04-30",{"name":5,"class":6},1]